Angelini Ventures is once again providing financial support to U.K. neurotechnology firm CoMind. The company partook in a recent $60 million funding round that was led by Plural and included participation from LocalGlobe and other existing investors. To date, CoMind has raised a total of $102.5 million.

This follow-on investment builds on Angelini Ventures’ co-lead participation in CoMind’s $27 million Series A funding round in (with Octopus Ventures) and underscores Angelini Ventures’ continued confidence in CoMind’s technology platform and its potential to transform bedside brain monitoring.

“This follow-on investment builds on the confidence we placed in CoMind’s visionary team when we co-led its Series A round in 2023. What started as backing a bold idea is now evolving into a concrete opportunity to revolutionize brain monitoring with genuine patient impact,” said Elia Stupka, managing director of Angelini Ventures and CoMind board member. “For Angelini Ventures, advancing brain health is a strategic priority, and CoMind represents the perfect complement to our biotech and drug discovery portfolio, bringing a revolutionary medtech solution that will have tangible impact on millions of patients.”

The funds will support CoMind’s pursuit of U.S. regulatory approval for the company’s principal product—CoMind One, the first device with the potential to non-invasively and continuously monitor brain blood flow, brain pressure, and other critical physiological parameters in a single measurement. The funds also will enable CoMind One to complete additional clinical trials, expand its team, and forge manufacturing partnerships.

CoMind One uses a low-power laser to transmit light through the scalp and skull into the brain tissue. The reflected signal is then combined with a second laser beam to create an interference pattern that is highly sensitive to the brain’s state. CoMind One is designed to measure three key brain health indicators simultaneously: cerebral blood flow, cerebral autoregulation, and intracranial pressure—something that has never been possible before. The technology also can potentially measure cerebral oxygenation, cerebral metabolism, and other critical physiological parameters, all without surgery.

CoMind One will make this critical information about a patient’s brain health easily and continually available at the bedside for the first time, allowing clinicians to make life-saving decisions. Further, by capturing extensive neurological information through a single sensor, CoMind’s technology provides the hardware foundation to power future AI tools to analyse patterns, predict complications, and guide treatment decisions in real-time.

“The brain is our most important organ, but the monitoring of the brain at the bedside is totally inadequate and archaic,” CoMind Founder/CEO James Dacombe stated. “CoMind’s products aim to give clinicians more information on the status of the brain to improve patient safety and outcomes.”

This technology is applicable to millions of patients across intensive care, surgery, and other neurocritical environments each year. Beyond intensive care, the technology shows promise to be used across the care continuum, according to CoMind.

Headquartered in London, CoMind develops breakthrough optical sensing technology to revolutionize brain monitoring and treatment. The company’s mission is to make routine, safe, and easy brain health monitoring available across all clinical settings, from intensive care units to operating rooms.

The venture capital arm of Angelini Industries, Angelini Ventures is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in biotech and health technology. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into category-leading companies. To date, Angelini Ventures has invested around €125 million into 22 companies covering various therapeutic areas and modalities. Angelini Ventures’ biotech portfolio includes Elkedonia, Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics, Freya Biosciences andAdcytherix. The Company’s digital health portfolio includes CoMind, Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis.

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries globally with revenues of more than €2 billion, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, and a deep knowledge of markets and business sectors make Angelini Industries a solid company within its sector.